@article{b03513baa1bf43389cd39eb9f640686f,
title = "Antidepressant use and 10-year incident fracture risk: The population-based Canadian Multicentre Osteoporosis Study (CaMoS)",
keywords = "Fragility fractures, Osteoporosis, Selective serotonin reuptake inhibitor, Serotonin and noradrenaline reuptake inhibitors",
author = "C. Moura and S. Bernatsky and M. Abrahamowicz and A. Papaioannou and L. Bessette and J. Adachi and D. Goltzman and J. Prior and N. Kreiger and T. Towheed and Leslie, {W. D.} and S. Kaiser and G. Ioannidis and L. Pickard and Fraser, {L. A.} and E. Rahme",
note = "Funding Information: Lisa-Ann Fraser has been on the speaker{\textquoteright}s bureau for Amgen. Jonathan D. Adachi has been a consultant/speaker for Amgen, Eli Lilly, Merck, Novartis, and Warner Chilcot, and has conducted clinical trials for Amgen, Eli Lilly, Merck, and Novartis. David Goltzman has been an advisory board member or consultant for Amgen, Eli Lilly, Merck Frosst, and Novartis. William Leslie has received speaker fees from Amgen, Eli Lilly, and Novartis and research grants from Amgen and Genzyme.",
year = "2014",
month = may,
doi = "10.1007/s00198-014-2649-x",
language = "English",
volume = "25",
pages = "1473--1481",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "5",
}
